Clinical Japanese Pharmaceutical Company Kowa claims Ivermectin exerts “antiviral effect”...

Japanese Pharmaceutical Company Kowa claims Ivermectin exerts “antiviral effect” against COVID


Japnese pharmaceutical and drug development company Kowa commented that the anti-parasite drug ivermectin demonstrates an “anti-viral” effect against the Omicron variant of COVID-19 in a joint non-clinical research

The company, in collaboration with Kitasato University since the start of the pandemic, didn’t mention any further details.

There is ongoing clinical research on the effect of ivermectin on COVID-19 patients and the subject has generated much controversy.

Noticeable vaccine cynic Joe Rogan, whose episodes on Spotify and other podcasting platforms have incited opposition by musicians Joni Mitchell and Neil Young, has long incited debate with his perspectives on the pandemic, government orders, and COVID-19 immunizations. Rogan claims that he has chosen to use Ivermectin over getting vaccinated. 

Japan has banned the marketing of Ivermectin as a cure for COVID-19. The FDA, the World Health Organization, the EU drug controller, and Merck (MRK.N), which manufactures the medication, have cautioned against its use due to an absence of any science-based proof that it has a medicinal impact.

In September 2021, the FDA website mentioned the developing interest in the medication for forestalling or treating COVID-19 in people yet said it had gotten different new of patients who had needed clinical consideration, including hospitalization, after self-medicating with it.

The utilization of ivermectin to treat COVID-19 is right now being researched in a UK preliminary trial by the University of Oxford. The researchers mentioned that their study is ongoing and refused to comment further

Numerous potential COVID-19 medicines that showed guarantee in test tubes failed to prove their efficacy in COVID-19 patients once considered in clinical trials, including the antimalarial hydroxychloroquine promoted by Donald Trump.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you